Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: TobagoJack who wrote (175842)	8/6/2021 9:09:43 AM
From: Julius Wong	Respond to of 218705

Sarepta upgraded to neutral at J.P. Morgan on regulatory and pipeline progress Aug. 05, 2021 9:00 AM ET Sarepta Therapeutics, Inc. (SRPT) By: Jonathan M Block, SA News Editor 1 Comment DKosig/iStock via Getty Images J.P. Morgan has upgraded shares of Sarepta Therapeutics (NASDAQ: SRPT) from underweight to neutral on what the firm sees as progress on both regulatory and pipeline fronts. However, the firm lowered its price target on shares to $87 from $92 (~29% upside). Analyst Anupam Rama says that his neutral rating is due in part to Sarepta's underperformance. The stock is down 60% year-to-date. However, he sees potential catalysts for the company. One is the pivotal study for SRP-9001 for Duchenne muscular dystrophy expected to begin next month. Another is what he calls broader progress with the pipeline. "Looking forward, we expect SRPT shares to be more of an in-line performer to the broader biotech markets, hence, the move to a Neutral rating," Rama writes.